Milestone Pharmaceuticals
6100 Royalmount Avenue
Montreal
Quebec
H4P 2R2
Canada
Tel: 514-496-3220
Fax: 514-496-3219
Website: http://www.milestonepharma.com/
Email: info@milestonepharma.com
113 articles about Milestone Pharmaceuticals
-
Milestone® Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium
4/17/2024
Milestone ® Pharmaceuticals Inc. today announced that it will present data on etripamil at the 30th Annual Cardiovascular Nursing Symposium held by the Preventive Cardiovascular Nurses Association on April 18-20th in Orlando, FL.
-
Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting
4/8/2024
Milestone® Pharmaceuticals Inc. a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced new clinical data demonstrating real-world application of etripamil, an investigational new drug, for conversion of recurrent paroxysmal supraventricular tachycardia.
-
Milestone® Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference
4/3/2024
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will deliver a company presentation at the 23rd Annual Needham Virtual Healthcare Conference on April 10, 2024 at 8:45 am ET.
-
Milestone® Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences
4/1/2024
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will present data on etripamil at two upcoming cardiology conferences this month.
-
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update
3/21/2024
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a regulatory and corporate update.
-
Milestone® Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference
2/29/2024
Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will participate in a corporate panel discussion at the TD Cowen 44th Annual Health Care Conference on March 5, 2024, at 10:30am ET.
-
Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants
2/29/2024
Milestone® Pharmaceuticals Inc. announced the pricing of its previously announced underwritten public offering of 16,666,667 of its common shares at a public offering price of $1.50 per share and in lieu of common shares, pre-funded warrants to purchase 3,333,333 common shares at a public offering price of $1.49 per pre-funded warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such pre-funded warrant.
-
Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants - February 28, 2024
2/28/2024
Milestone® Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, announced that it has commenced an underwritten public offering of its common shares, and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares.
-
Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT
2/26/2024
Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced plans to resubmit the New Drug Application (NDA) for etripamil to the U.S. Food and Drug Administration (FDA) for paroxysmal supraventricular tachycardia (PSVT).
-
Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT
12/26/2023
Milestone® Pharmaceuticals Inc. announced that the Company received a Refusal to File letter from the U.S. Food and Drug Administration for the New Drug Application for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia.
-
Milestone Announces Agreement with Bioline Supply to Distribute the CompuFlo® Epidural System and Related Disposables Across Spain
11/28/2023
Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced it has entered into an agreement with Bioline Supply to distribute the CompuFlo® Epidural System and related disposables in Spain.
-
Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference
11/21/2023
Milestone Pharmaceuticals Inc. announced that members of its management team will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28, 2023, at 10:30 a.m. Eastern Time.
-
Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates
11/13/2023
Milestone Pharmaceuticals Inc. reported financial results for the third quarter ended September 30, 2023, and provided a clinical and corporate update.
-
Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023
11/11/2023
Milestone Pharmaceuticals Inc. announced positive Phase 2 data that show etripamil nasal spray resulted in rapid and statistically superior ventricular rate reduction and improved symptom-relief in patients with atrial fibrillation with rapid ventricular rate compared to placebo.
-
Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR
11/7/2023
Milestone Pharmaceuticals Inc. announced that the Company will host a virtual investor and analyst webcast on Monday, November 13, 2023 at 8:00 a.m. ET.
-
Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil
10/24/2023
Milestone® Pharmaceuticals Inc. announced the submission of a New Drug Application to the U.S. Food and Drug Administration for etripamil for the treatment of paroxysmal supraventricular tachycardia.
-
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)-October 6, 2023
10/6/2023
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a total of 122,000 options (the "Options") to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the "Plan"), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment of three new hires.
-
Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
9/5/2023
Milestone Pharmaceuticals Inc. announced that members of its management team will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023 at 9:00 a.m. ET.
-
Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update
8/10/2023
Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2023, and provided a clinical and corporate update.
-
Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet
6/20/2023
Milestone Pharmaceuticals Inc. today announced the publication of results in The Lancet from the Phase 3 RAPID clinical trial evaluating etripamil nasal spray, the Company's investigational calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT).